Prosecution Insights
Last updated: November 04, 2026

Anpac Bio-Medical Science Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Anpac Bio-Medical Science Co. Ltd. operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This indicates a focused effort to protect a specific bio-medical innovation through the patent office. The current level of activity suggests that the company is in a critical stage of securing rights for its core diagnostic or therapeutic technology.

The prosecution is handled by a distinct examiner and 1 distinct art unit. This suggests that the company's current filings fall within a specialized technical category. CHRISTOPHER L CHIN is the busiest examiner for the portfolio, currently managing the busiest examiner pending office action. This examiner is the only official currently reviewing the company's pending claims, which provides an opportunity for a consistent and focused technical dialogue.

For the legal team, the presence of the distinct art unit simplifies the procedural landscape. Because there is 1 pending office action, the prosecution strategy is entirely centered on the feedback from CHRISTOPHER L CHIN. This allows for a concentrated response to any rejections within the Biotechnology & Pharmaceuticals sector, ensuring that the technical arguments are specifically tailored to the examiner's requirements and the standards of the assigned art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHIN, CHRISTOPHER L 1 80.6% +22.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17394722 MICRO-DEVICES FOR DISEASE DETECTION AND TREATMENT CHIN, CHRISTOPHER L —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17394722 MICRO-DEVICES FOR DISEASE DETECTION AND TREATMENT CHIN, CHRISTOPHER L —

Top Art Units

Art UnitApps
1677 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17394722 MICRO-DEVICES FOR DISEASE DETECTION AND TREATMENT CHIN, CHRISTOPHER L 1677 §102§112Other Non-Final OA — Pending Aug 05, 2021

Managing Anpac Bio-Medical Science Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Anpac Bio-Medical Science Co. Ltd. have?

Anpac Bio-Medical Science Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Anpac Bio-Medical Science Co. Ltd. applications?

Christopher L Chin has the most, with 1 of Anpac Bio-Medical Science Co. Ltd.'s pending office actions.

What technology area are Anpac Bio-Medical Science Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month